FDA Cites Respi Care As Part Of Pharmacy Compounding Enforcement
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency issues its second “warning letter” in a month citing a pharmacy’s compounding operations as comparable to that of a drug manufacturer. The agency also notes cGMP violations observed during an inspection of Respi Care’s facility in Puerto Rico.